Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Story A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. First Published: 1/14/2026. 
In Brief - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. They also carry substantial downside risk. But even conservative investors shouldn't automatically dismiss recently IPO'ed stocks—some may deserve a place in buy-and-hold portfolios. Most crypto investors wake up, check their phone, and pray the line is green. That's a terrible way to invest. A "Market Neutral" approach extracts profit from volatility itself. The more the market moves, up or down, the more opportunities emerge. Volatility becomes the gift, not the enemy. Today and tomorrow's sessions break down exactly how to structure your portfolio to thrive in chaos. Every attendee receives a free weekly trade alert plus $10 in Bitcoin. Register now and learn how to profit regardless of market direction. One biotechnology company in the healthcare sector that recently went public could be such a candidate. Last Year's IPO Success Stories Last year is a strong reminder why IPOs shouldn't be written off by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its nearly 359% gain before the stock had been listed 30 days, but longer-term holders are still enjoying strong returns. Other listings, such as Medline (NASDAQ: MDLN), counter the misconception that IPOs are only high-risk startups. The medical products and services provider—founded in 1966—debuted publicly in December 2025 and already has a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its packaged bacon—waited 89 years before its IPO. Since going public in January 2025 the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation. That targeted approach can minimize harm to healthy tissue compared with conventional radiation therapies. Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will approach $35 billion by 2030, a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant contributor. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding decisions in 2025 slowed new listings from the healthcare sector. Aktis, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million—one of the larger biotech IPO fundraises in recent memory. The company now has a market capitalization of about $3.34 billion. According to the company's prospectus, Aktis' executive team includes drug development, approval, and commercialization experts, with members of management having helped bring 14 products to FDA approval. On a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs using proprietary technology designed to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting major industry interest. According to Reuters, Eli Lilly (NYSE: LLY) purchased $100 million worth of AKTS shares, anchoring the IPO. That investment builds on a 2024 partnership between the two companies to develop tumor-targeting radiopharmaceuticals. Under that deal, Aktis received $60 million in cash plus an equity investment from Eli Lilly, and Lilly may pay potential milestone payments exceeding $1 billion. The significance of Eli Lilly's backing is notable. With a market cap around $1.01 trillion, Lilly is one of the largest pharmaceutical firms globally. Its net income jumped nearly 109% year-over-year from 2023 to 2024, and that trend may continue when Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million share purchase, Eli Lilly—maker of Zepbound—now has a sizable financial interest in Aktis' success.
| 
